国药现代(600420.SH)：盐酸米那普仑获得化学原料药上市申请批准

Core Viewpoint - The approval of the active pharmaceutical ingredient (API) for Minaprine Hydrochloride by the National Medical Products Administration (NMPA) signifies a positive development for the company, enhancing its market competitiveness and resource allocation [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Jiangsu Weichida Pharmaceutical Co., Ltd., received the approval notice for the listing application of Minaprine Hydrochloride [1] - Minaprine Hydrochloride is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) developed by Pierre Fabre, intended for the treatment of major depressive disorder [1] - The approval indicates that the API meets national pharmaceutical approval technical standards, allowing for production and sales in the domestic market [1] Group 2: Strategic Implications - The approval will assist the company in advancing the industrial chain integration of related products, optimizing resource allocation and industrial layout [1] - This development is expected to enhance the company's product market competitiveness and positively impact future growth [1] - The matter is not anticipated to have a significant impact on the company's current operating performance [1]